(Q57904843)

English

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-?B ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma

scientific article published on 01 December 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

0 references

multiple myeloma

1 reference

based on heuristic

inferred from title

Athanasios Dimopoulos

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Peter I Croucher

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

author name string

Evangelos Terpos

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Amin Rahemtulla

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Kostas Zervas

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Athanasios Anagnostopoulos

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Anastasia Pouli

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Eirini Katodritou

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Evgenia Verrou

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Elisavet-Christine Vervessou

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Deborah J Heath

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Andrew Chantry

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

language of work or name

0 references

publication date

1 December 2006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

British Journal of Haematology

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

135

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

688-692

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

A crosstalk between myeloma cells and marrow stromal cells stimulates production of DKK1 and interleukin-6: a potential role in the development of lytic bone disease and tumor progression in multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06356.X

21 January 2018

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06356.X

21 January 2018

Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06356.X

21 January 2018

High serum bone-specific alkaline phosphatase level after bortezomib-combined therapy in refractory multiple myeloma: possible role of bortezomib on osteoblast differentiation

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06356.X

21 January 2018

New insights into the pathophysiology and management of bone disease in multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06356.X

21 January 2018

Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06356.X

21 January 2018

Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06356.X

21 January 2018

The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling, through the reduction of sRANKL/osteoprotegerin ratio

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06356.X

21 January 2018

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06356.X

21 January 2018

Response to bortezomib is associated to osteoblastic activation in patients with multiple myeloma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2006.06356.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2006.06356.X

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17107351%20AND%20SRC:MED&resulttype=core&format=json

21 December 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57904843&oldid=2030819529"